The S-3 resale overhang (237% of float) will pressure the stock regardless of pipeline updates. Watch for MHRA approval on the TXM challenge trial as the next binary catalyst — approval could trigger the Series A milestone warrant exercise ($10M). Until the FDA clinical hold is resolved, the stock remains a high-risk speculative name with severe dilution overhang.
Price Chart
Executive Summary
Traws Pharma reported Q1 2026 results with zero revenue and a net loss of $7.1M ($-0.53/share), a sharp reversal from the $21.5M net income in Q1 2025 driven by a non-cash warrant liability gain. The company's cash burn continues, with cash dropping to $3.1M at quarter-end before the April PIPE infusion. The S-3 resale registration filed 7 days ago creates massive overhang (237% of shares outstanding), and the FDA clinical hold on the lead TXM program remains unresolved. The combination of negative operating results, dilutive overhang, and regulatory uncertainty makes this a bearish filing.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $0.0M vs $0.06M in Q1 2025
- Net loss of $7.1M ($-0.53/share) vs net income of $21.5M ($2.17/share) in Q1 2025
- Cash and cash equivalents fell to $3.1M at March 31, 2026 from $3.8M at December 31, 2025
- R&D expense doubled to $4.9M from $2.5M YoY as cash burn accelerated
- S-3 filed May 8, 2026 registers 35.9M shares for resale (237% of outstanding shares)
- FDA clinical hold on lead TXM program remains unresolved
- April 2026 PIPE provided $10M upfront with up to $50M in milestone-based warrants
- Shares outstanding grew to 15.15M as of May 12, 2026 from 10.16M at March 31, 2026
- Stockholders' deficit widened to -$5.3M from -$0.6M at year-end 2025
Financial Impact
Q1 2026 net loss of $7.1M; cash burn of ~$0.7M/month; $10M PIPE upfront provides runway into Q1 2027
Risk Factors
- Massive dilution from S-3 resale registration (35.9M shares, 237% of outstanding)
- FDA clinical hold on TXM program unresolved with no clear timeline
- Cash burn accelerating with R&D spend doubling YoY
- Stockholders' deficit worsening, going concern risk if milestones not met
- Milestone-based warrants may not be exercised, limiting future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061771 |
| Document: tm2614707d1_8k.htm | 0001104659-26-061771 |
| Document: 0001104659-26-061771-index-headers.html | 0001104659-26-061771 |
| Document: 0001104659-26-061771-index.html | 0001104659-26-061771 |
| Document: 0001104659-26-061771.txt | 0001104659-26-061771 |
| 8-K Data (Synthetic) | 0001104659-26-061771 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3400 (+2.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers